Jump to: navigation, search
Clinical data
Trade namesPansporin
AHFS/Drugs.comInternational Drug Names
Routes of
Intravenous, intramuscular
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability60% (intramuscular)
Protein binding40%
Elimination half-lifeApproximately 1 hour
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass525.631 g/mol
3D model (JSmol)

WikiDoc Resources for Cefotiam


Most recent articles on Cefotiam

Most cited articles on Cefotiam

Review articles on Cefotiam

Articles on Cefotiam in N Eng J Med, Lancet, BMJ


Powerpoint slides on Cefotiam

Images of Cefotiam

Photos of Cefotiam

Podcasts & MP3s on Cefotiam

Videos on Cefotiam

Evidence Based Medicine

Cochrane Collaboration on Cefotiam

Bandolier on Cefotiam

TRIP on Cefotiam

Clinical Trials

Ongoing Trials on Cefotiam at Clinical Trials.gov

Trial results on Cefotiam

Clinical Trials on Cefotiam at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cefotiam

NICE Guidance on Cefotiam


FDA on Cefotiam

CDC on Cefotiam


Books on Cefotiam


Cefotiam in the news

Be alerted to news on Cefotiam

News trends on Cefotiam


Blogs on Cefotiam


Definitions of Cefotiam

Patient Resources / Community

Patient resources on Cefotiam

Discussion groups on Cefotiam

Patient Handouts on Cefotiam

Directions to Hospitals Treating Cefotiam

Risk calculators and risk factors for Cefotiam

Healthcare Provider Resources

Symptoms of Cefotiam

Causes & Risk Factors for Cefotiam

Diagnostic studies for Cefotiam

Treatment of Cefotiam

Continuing Medical Education (CME)

CME Programs on Cefotiam


Cefotiam en Espanol

Cefotiam en Francais


Cefotiam in the Marketplace

Patents on Cefotiam

Experimental / Informatics

List of terms related to Cefotiam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Cefotiam is a parenteral second-generation cephalosporin antibiotic. It has broad-spectrum activity against Gram-positive and Gram-negative bacteria. As a beta-lactam, its bactericidal activity results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins.

Cefotiam was launched as Pansporin in February 1981 by Takeda Pharmaceutical of Japan and has been available as a generic since February 1993.

Mechanism of action

Cefotiam inhibits final cross-linking stage of peptidoglycan production, thus inhibiting bacterial cell wall synthesis. It has similar or less activity against Gram-positive staphylococci and streptococci, but is resistant to some beta-lactamases produced by Gram-negative bacteria. It is more active against many of the Enterobacteriaceae including Enterobacter, E. coli, Klebsiella, Salmonella and indole-positive Proteus species.

In clinical use, high concentrations of cefotiam are observed in several tissues (kidney, heart, ear, prostate, and genital tract), as well as in fluids and secretions (bile, ascitic fluid).

Spectrum of bacterial susceptibility

Cefotiam has a broad spectrum of activity and has been used to treat infections caused by a number of enteric bacteria and bacteria responsible for causing skin infections. The following represents MIC susceptibility data for a few medically significant bacteria.

  • Bacteroides fragilis: - 16 - >128 μg/ml
  • Clostridium difficile: >128 μg/ml
  • Staphylococcus aureus: 0.25 - 32 μg/ml



This drug is indicated for prophylaxis for surgical infection, postoperative infections, bacterial septicaemia, bone and joint infections, cholangitis, cholecystitis, peritonitis, prostatitis, pyelonephritis, respiratory tract infections, skin and soft tissue infections, cystitis, urethritis, and infections caused by susceptible organisms. It does not have activity against Pseudomonas aeruginosa.


For adults, the dose is up to 6 grams daily by intravenous or intramuscular route in divided doses according to severity of infection. In patients with renal impairment a dose reduction may be needed.

Adverse effects

Side effects include nausea and vomiting, diarrhoea, hypersensitivity reactions, nephrotoxicity, convulsions, CNS toxicity, hepatic dysfunction, haematologic disorders, pain at injection site, thrombophloebitis, pseudomembranous colitis, and superinfection with prolonged use.

External links

  • Müller R, Böttger C, Wichmann G (2003). "Suitability of cefotiam and cefuroxime axetil for the perioperative short-term prophylaxis in tonsillectomy patients". Arzneimittelforschung. 53 (2): 126–32. doi:10.1055/s-0031-1297083. PMID 12642969.
  • Kolben M, Mandoki E, Ulm K, Freitag K (2001). "Randomized trial of cefotiam prophylaxis in the prevention of postoperative infectious morbidity after elective cesarean section". Eur J Clin Microbiol Infect Dis. 20 (1): 40–2. doi:10.1007/s100960000365. PMID 11245321.
  • Shimizu S, Chen K, Miyakawa S (1996). "Cefotiam-induced contact urticaria syndrome: an occupational condition in Japanese nurses". Dermatology. 192 (2): 174–6. doi:10.1159/000246352. PMID 8829507.